TGFB1 and cardiomyopathy: TGFβ is a well-known driver of dilative ventricular remodeling in dystrophic and non-dystrophic cardiomyopathies, as it stimulates myocardial fibrosis [104,105], and angiotensin-converting enzyme inhibitors (ACEi) are effective against cardiac remodeling, because they block downstream TGFβ activation [106].